Personalized mRNA Melanoma Vaccine: INTerpath-001 for USMLE

Adding a personalized mRNA cancer vaccine to pembrolizumab after surgery for high-risk melanoma reduced the risk of recurrence or death by 42% compared with pembrolizumab alone. The result comes from the phase 3 INTerpath-001 trial, presented at the ESMO Congress 2026. It is a conference presentation, not a final publication, and overall survival data are still immature.

What happened

INTerpath-001 tested a vaccine called intismeran autogene. Each patient's tumor is sequenced to identify neoantigens, which are abnormal proteins specific to that person's cancer. Up to 34 of these neoantigens are encoded in mRNA, with the goal of helping the immune system recognize and attack any remaining cancer cells. The vaccine was given together with pembrolizumab and compared with pembrolizumab plus placebo.

The trial randomly assigned 1,137 adults who had undergone surgery for stage IIB–IV cutaneous melanoma. Of these, 757 received pembrolizumab plus intismeran and 380 received pembrolizumab plus placebo.

After a median follow-up of 24.6 months:

• Recurrence or death: HR 0.58 (95% CI 0.45–0.75; p<0.001). At two years, 82.2% of patients on the combination were alive without recurrence, versus 70.0% on pembrolizumab alone.
• Distant metastasis or death: HR 0.62 (95% CI 0.45–0.85; p=0.002), a 38% reduction. At two years, 88.5% versus 80.2% were alive without distant metastasis.
• Subgroups: benefits were similar across lower- and higher-risk disease groups.
• Overall survival: immature at this interim analysis, with no statistically significant difference (HR 0.77; 95% CI 0.45–1.31).
• Safety: grade 3 or higher adverse events occurred in 23.6% of the combination group and 20.3% of the pembrolizumab-only group. Fever (52.2% vs 8.2%), injection-site pain (51.0% vs 9.5%) and fatigue (38.5% vs 29.7%) were the most common side effects with the combination. Side effects tied to the injections were generally low grade and transient.

Why it matters

Anti-PD-1 therapy such as pembrolizumab is a standard treatment after surgery for high-risk melanoma, yet many patients still relapse. Earlier phase 3 trials that added a second checkpoint inhibitor did not improve on anti-PD-1 alone. This trial tried a different strategy: instead of removing another brake on T cells, it gives the immune system a tumor-specific target.

Lead author Dr. Georgina Long called it the first phase 3 study to show that a treatment built from the unique "fingerprint" of a patient's own tumor can reduce the risk of recurrence or death from cancer. Dr. James Larkin, scientific co-chair of the ESMO Congress 2026 who was not involved in the study, called the reduction in relapse risk clinically significant and the combination very well tolerated.

Trials are already underway in lung, bladder and kidney cancer. Larkin also stressed that this is very different from vaccinating people without cancer to prevent it. Here the vaccine is used as adjuvant treatment in people who have already had a tumor removed.

What to know for the USMLE

This news ties together several topics that appear on Step 1 and Step 2 CK.

• Pembrolizumab is a monoclonal antibody against PD-1 on T cells. Tumors express PD-L1, which binds PD-1 and delivers an inhibitory signal. Blocking this interaction reverses T-cell exhaustion. Know it as a checkpoint inhibitor, along with the anti-CTLA-4 agent ipilimumab and the PD-L1 inhibitors.
• Immune-related adverse events of checkpoint inhibitors are classic exam material: colitis, pneumonitis, hepatitis, thyroiditis, hypophysitis, adrenal insufficiency, type 1 diabetes and rash. The mechanism is loss of self-tolerance. In this trial, the extra side effects with the vaccine were mainly fever, injection-site pain and fatigue.
• Neoantigens arise from somatic mutations in tumor DNA and are not subject to central tolerance, because they are not present in normal tissue. This is why they are attractive targets. Melanoma has a high mutational burden because UV exposure causes pyrimidine dimers and C→T transitions. This is a major reason melanoma responds to checkpoint inhibitors.
• mRNA vaccine pathway: mRNA is translated in the host cell cytoplasm. The resulting proteins are degraded by the proteasome, and the peptides are transported into the ER by TAP and loaded onto MHC class I. They are then presented to CD8+ cytotoxic T cells. Exogenous or cross-presented antigen also engages CD4+ helper T cells through MHC class II. Remember that mRNA does not integrate into the genome.
• Melanoma basics: it arises from melanocytes of neural crest origin. Breslow thickness is the most important prognostic factor for localized disease. Immunohistochemical markers include S-100, HMB-45 and Melan-A. BRAF V600E is the most common driver mutation, treated with BRAF/MEK inhibitors, a different class from the drugs discussed here.
• Biostatistics:
• Hazard ratio: an HR of 0.58 means a 42% relative reduction in the hazard of the event. A 95% CI that excludes 1 (0.45–0.75) indicates statistical significance. The overall survival CI (0.45–1.31) crosses 1, so no difference can be claimed.
• Absolute risk: the two-year recurrence-free rates differ by 12.2 percentage points (82.2% vs 70.0%). A rough number needed to treat is about 8 over two years. This is only an illustration from the reported estimates, not a figure from the study.
• Surrogate endpoint: recurrence-free survival is not the same as overall survival.
• Interim analysis: early looks at data can change as follow-up lengthens.
• Adjuvant therapy: treatment given after surgery to eliminate micrometastatic disease.

Limitations

• Conference data. The results were presented at ESMO 2026 and are not a final publication. Details may change with full peer-reviewed reporting.
• Short follow-up. Median follow-up was 24.6 months. Whether the early benefit holds is not yet known.
• No survival benefit shown yet. Overall survival was immature and the difference was not statistically significant (HR 0.77; 95% CI 0.45–1.31). Long said longer follow-up is needed to show an effect on melanoma-specific and overall survival.
• Unclear who benefits most. Benefit looked similar across subgroups, but Long noted that which patients benefit most remains to be determined.
• Limited population. Participants were adults with surgically treated stage IIB–IV cutaneous melanoma. The results do not apply to other melanoma types, other cancers or people without cancer.
• More side effects. Fever and injection-site pain were far more common with the vaccine. Grade 3 or higher events were numerically higher (23.6% vs 20.3%), although injection-related effects were generally low grade and transient.

This article is educational and is not medical advice for any individual.

FAQ

What is intismeran autogene?

It is a personalized mRNA-based cancer vaccine. A patient's tumor is sequenced to find neoantigens, and up to 34 of them are encoded in mRNA to help the immune system recognize and attack residual cancer cells.

Did the vaccine improve survival in melanoma?

Not yet demonstrated. It reduced the risk of recurrence or death (HR 0.58), but overall survival data were immature and showed no statistically significant difference at this interim analysis (HR 0.77; 95% CI 0.45–1.31).

Is this a vaccine to prevent melanoma?

No. It was tested after surgery in people who already had high-risk melanoma, together with pembrolizumab. Larkin emphasized that this differs from vaccinating healthy people to reduce later cancer risk.

Key takeaways

• In the phase 3 INTerpath-001 trial, intismeran autogene plus pembrolizumab reduced the risk of recurrence or death by 42% (HR 0.58) versus pembrolizumab alone in resected stage IIB–IV melanoma. Two-year recurrence-free survival was 82.2% versus 70.0%.
• Overall survival is immature and not significantly different yet. The data are interim and were presented at a conference, so longer follow-up and full publication are needed.
• For the USMLE, connect PD-1 blockade, neoantigens, MHC I presentation to CD8+ T cells and hazard ratio interpretation. These concepts explain both the mechanism and how to read the trial.